167
Participants
Start Date
September 30, 2014
Primary Completion Date
January 31, 2016
Study Completion Date
January 31, 2016
nalbuphine HCl ER
nalbuphine HCl ER
Newtown Dialysis Center Inc, Astoria
Nephrology Research Consortium, Bethlehem
Delaware Valley Nephrology, Philadelphia
Dialysis Clinic, Inc., Philadelphia
Brookview Hills Research Associates LLC, Winston-Salem
Wake Nephrology Associates PA, Raleigh
Durham Nephrology Associates, Durham
Carolina Diabetes and Kidney Center, Sumter
Renal Physicians of Georgia, Macon
Southwest Georgia Nephrology Clinic PC, Albany
DaVita Central Orlando Dialysis, Winter Park
Pines Clinical Research, Pembroke Pines
Genesis Clinical Research, Tampa
Nephrology Associates PC, Birmingham
University South Alabama Medical Center, Mobile
SouthEast Renal Research Institute, Chattanooga
McComb Limited Care Facility, McComb
University of Cincinnati, Cincinnati
Nephrology Center DBA Paragon Health, Kalamazoo
Fresenius Medical Care of Evergreen Park, Evergreen Park
Kidney Associates of Kansas City PC, Kansas City
U.S. Renal Care Inc., Pine Bluff
U.S. Renal Care Inc, Mansfield
U.S. Renal Care, Inc., Fort Worth
U.S. Renal Care Inc., Fort Worth
Nephrology-Hypertension Associates of Central New Jersey PA, North Brunswick
Pacific Renal Research Institute, Meridian
Arizona Kidney Disease and Hypertension Center, Phoenix
Renal Medicine Associates, Albuquerque
Mark Lee MD, Inc, Whittier
North America Research Institute, Azusa
Pegasus Dialysis Center, Bakersfield
Central Nephrology Medical Group, Bakersfield
Nephrology and Hypertension Associates PC, Middlebury
Western New England Renal and Transplant Association, Springfield
Lead Sponsor
Trevi Therapeutics
INDUSTRY